Cellotype-phenotype associations using 'organoid villages'

Masaki Kimura; Takanori Takebe

doi:10.1016/j.tem.2024.03.001

Cellotype-phenotype associations using 'organoid villages'

Trends Endocrinol Metab. 2024 Apr 3:S1043-2760(24)00063-8. doi: 10.1016/j.tem.2024.03.001. Online ahead of print.

Authors

Masaki Kimura¹, Takanori Takebe²

Affiliations

¹ Center for Stem Cell and Organoid Medicine (CuSTOM), Division of Gastroenterology, Hepatology and Nutrition, Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
² Center for Stem Cell and Organoid Medicine (CuSTOM), Division of Gastroenterology, Hepatology and Nutrition, Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA; Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan; Institute of Research, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, Japan. Electronic address: takanori.takebe@cchmc.org.

PMID: 38575442
DOI: 10.1016/j.tem.2024.03.001

Abstract

En masse phenotyping technology, using massively mosaic donor-derived cells and organoids, can offer enriched insights for cellotype-phenotype association in a cell-type-specific regulatory context. This emerging approach will help to discover biomarkers, inform genetic-epigenetic interactions and identify personalized therapeutic targets, offering hope for precision medicine against highly heterogeneous metabolic diseases.

Keywords: MASLD/MASH; cellotype; en masse phenotyping; iPSC; organoid.